Feasibility study on measuring selected proteins in malignant melanoma tissue by SRM quantification

Charlotte Welinder, Göran Jönsson, Christian Ingvar, Lotta Lundgren, Bo Baldetorp, Haìškan Olsson, Thomas Breslin, Melinda Rezeli, Bo Jansson, Thomas Laurell, Thomas E. Fehniger, Elisabet Wieslander, Krzysztof Pawlowski, György Marko-Varga

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Currently there are no clinically recognized molecular biomarkers for malignant melanoma (MM) for either diagnosing disease stage or measuring response to therapy. The aim of this feasibility study was to develop targeted selected reaction monitoring (SRM) assays for identifying candidate protein biomarkers in metastatic melanoma tissue lysate. In a pilot study applying the SRM assay, the tissue expression of nine selected proteins [complement 3 (C3), T-cell surface glycoprotein CD3 epsilon chain E (CD3E), dermatopontin, minichromosome maintenance complex component (MCM4), premelanosome protein (PMEL), S100 calcium binding protein A8 (S100A8), S100 calcium binding protein A13 (S100A13), transgelin-2 and S100B] was quantified in a small cohort of metastatic malignant melanoma patients. The SRM assay was developed using a TSQ Vantage triple quadrupole mass spectrometer that generated highly accurate peptide quantification. Repeated injection of internal standards spiked into matrix showed relative standard deviation (RSD) from 6% to 15%. All nine target proteins were identified in tumor lysate digests spiked with heavy peptide standards. The multiplex SRM peptide assay panel was then measured and quantified on a set of frozen MM tissue samples obtained from the Malignant Melanoma Biobank collected in Lund, Sweden. All nine proteins could be accurately quantified using the new SRM assay format. This study provides preliminary data on the heterogeneity of biomarker expression within MM patients. The S100B protein, which is clinically used as the pathology identifier of MM, was identified in 9 out of 10 MM tissue lysates. The use of the targeted SRM assay provides potential advancements in the diagnosis of MM that can aid in future assessments of disease in melanoma patients.

Original languageEnglish (US)
Pages (from-to)1315-1326
Number of pages12
JournalJournal of Proteome Research
Volume13
Issue number3
DOIs
StatePublished - Mar 7 2014
Externally publishedYes

Keywords

  • cancer tissue
  • genes
  • malignant melanoma
  • mass spectrometry
  • mRNA
  • protein sequencing
  • proteomics

ASJC Scopus subject areas

  • Biochemistry
  • Chemistry(all)

Fingerprint Dive into the research topics of 'Feasibility study on measuring selected proteins in malignant melanoma tissue by SRM quantification'. Together they form a unique fingerprint.

Cite this